urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2020-8-3-103-110urovest-370Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEГенетическое исследование как метод оценки предрасположенности к развитию рака предстательной железыGenetic research as a method for assessing susceptibility to prostate cancerhttps://orcid.org/0000-0001-5183-5153РеваС. А.RevaS. A.

Сергей Александрович Рева - кандидат медицинских наук; заведующий отделением онкоурологии и андрологии НИЦ урологии ФГБОУ ВО ПСПбГМУ им. акад. И.П. Павлова Минздрава России

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Sergey A. Reva - M.D., Cand.Sc.(M); Head, Oncological Urology and Andrology Division.

197022, St. Petersburg, 6-8 Lev Tolstoy St.

sgreva79@mail.ruhttps://orcid.org/0000-0001-8478-6650КудиноваН. И.KudinovaN. I.

Ника Игоревна Кудинова - студентка лечебного факультета.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8; тел.: +7 (952) 243-88-93

Nika I. Kudinova - Student, Faculty of the General Medicine.

197022, St. Petersburg, 6-8 Lev Tolstoy St.; tel.: +7 (952) 243-88-93

hamsteri1@mail.ruhttps://orcid.org/0000-0002-4998-3699ЛапинС. В.LapinS. V.

Сергей Владимирович Лапин - кандидат медицинских наук; заведующий лабораторией диагностики аутоиммунных заболеваний НМЦ по молекулярной медицине урологии.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Sergey V. Lapin - M.D., Cand.Sc.(M); Head, Laboratory of the Autoimmune Disease Diagnostics, Scientific Medical Center for Molecular Medicine in Urology.

197022, St. Petersburg, 6-8 Lev Tolstoy St.

svlapin@mail.ruhttps://orcid.org/0000-0003-3460-3427ПетровС. В.PetrovS. B.

Сергей Борисович Петров - доктор медицинских наук, профессор; руководитель НИЦ урологии.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Sergey B. Petrov - M.D., Dr.Sc.(M); Full Prof.; Head, Research Center of Urology.

197022, St. Petersburg, 6-8 Lev Tolstoy St.

petrov-uro@yandex.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава РоссииРоссияPavlov First Saint Petersburg State Medical UniversityRussian Federation20200410202083103110Copyright © Рева С.А., Кудинова Н.И., Лапин С.В., Петров С.В., 20202020Рева С.А., Кудинова Н.И., Лапин С.В., Петров С.В.Reva S.A., Kudinova N.I., Lapin S.V., Petrov S.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/370

В статье представлен анализы литературных источников, описывающих связь между патологическими аллелями некоторых генов и рака предстательной железы, которые, могут быть использованы в качестве определения риска развития рака предстательной железы. с этой целью оценивались патологические аллели таких генов, как ген HOXB13 (251G/A, G84E), ген BRcA1 (5382insc, 185delAG, 4153delA, 3819delGTAAA, 3875delGTCT,300T/ G,2080delA) и BRcA2, ген cHEK2 (1100delc, I157T), ген ELAc2 (Leu217, Thr541, 650T, 1618А), ген cDH1 (160c/A), ген AR (тринуклеотидные повторы cAG), ген VDR (rs1544410, rs10875692, rs7301552, rs7975232, rs731236), гены семейства GST (нулевые аллели GSTM1 и GSTT1, однонуклеотидные замены гена GSTp1 313A/G и 341СД), а так же гены синдрома Блума. Ряд онкогенов и патологических аллелей имеют доказанную статистическую связь с повышенным риском рака предстательной железы. при этом отмечается взаимосвязь этнической принадлежности и повышенного риска возникновения рака предстательной железы при наличии патологических аллелей таких генов, как ген BRcA1, ген AR, ген VDR и гены семейства GST.

The article presents the analyzes of literature sources describing the relationship between pathological alleles of some genes and prostate cancer, which can be used to determine the risk of developing prostate cancer. Mutations of the genes such as HOXB13 (251G/A, G84E), BRCA1 (5382insC, 185delAG, 4153delA, 3819delGTAAA, 3875delGTCT, 300T/G,2080delA) and BRCA2,CHEK2 (1100delC, I157T), ELAC2 (Leu217, Thr541, 650T, 1618a), cdh1 gene (160C/a), AR gene (CAG trinucleotide repeats), VDR gene (rs1544410, rs10875692, rs7301552, rs7975232, rs731236), GST family genes (null alleles of GSTM1 and GSTT1, single-nucleotide substitutions of GSTP1 313a/G and 341c/T), as well as Bloom's syndrome genes were studied. We described what mutations have a proven statistical association with an increased risk of prostate cancer. At the same time, the correlation between the patient's ethnicity and an increased risk of prostate cancer, when there are mutations of BRCA1, AR, VDR and GST family genes, is also noted.

рак предстательной железыгенетические исследованиямутации геновprostate cancergenetic researchgene-mutationsReferencesНемцова М.В. применение ДНК- и РНК-маркеров в практической онкологии. Клиническая лабораторная диагностика. 2013;9: 27-29.Nemcova M.V. Primenenie DNK- i RNK-markerov v prakticheskojonkologii. Klinicheskaya laboratornaya diagnostika. 2013;9: 27-29. (In Russ.)Торопова Н.Е., Закамова Е.В., Тетерина Ю.Ю., Козлов С.В., Тимофеева Н.В., Морошкина Г.П., Нетелева С.Г., Липатова Е.Н., Трухова Л.В., Фролова Е.В. Молекулярногенетические исследования в практике онкологической клиники. Известия Самарского научного центра Российской академии наук. 2015;17(2-3):690-696. eLIBRARY ID:24238979Toropova N.E., Zakamova E.V., Teterina Yu., Kozlov S., Timofeeva N., Moroshkina G., Neteleva S., Lipatova E., Trukhova L., Frolova E. Molecular and genetic research in practice of oncology clinic. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2015;17(2-3):690-696. (In Russ.). eLIBRARY ID: 24238979Оспанов Е.А., Адылханов Т.А. прогностическая значимость Ki-67, p53 у больных раком предстательной железы и их корреляция со стандартными показателями. Наука и Здравоохранение. 2019;21(4):80-89. eLIBRARY ID: 40615007Ospanov E.A., Adylkhanov T.A. Prognostic significance of Ki-67, p53 in patiens with prostate cancerand their correlation with standart indicators. Science & Healthcare. 2019;21(4):80-89 (In Russ.). eLIBRARY ID: 40615007Кульченко Н.Г., Толкачев А.О. Рак предстательной железы в 21 веке. Обзор литературы. Вестник медицинского института «РЕАВИЗ». 2017;6(30):111-118. eLIBRARY ID: 32470973Kulchenko N.G., Tolkachev A.O. Prostate cancer in the 21st century: a literature review. Vestnik medicinskogo instituta «REAVIZ». 2017;6(30):111-118. (In Russ.). eLIBRARY ID: 32470973Канаева М.Д., Воробцова И.Е. Генетические маркеры предрасположенности к возникновению рака предстательной железы. Онкоурология. 2015;11(3):16-23. https://doi.org/10.17650/1726-9776-2015-11-3-16-23Kanaeva M.D., Orobtsova I.E. Genetic predisposition markers for prostate cancer. Cancer Urology. 2015;11(3):16-23. (In Russ.). https://doi.org/10.17650/1726-9776-2015-11-3-16-23Norris JD, Chang C-Y, Wittmann BM, Stein R, Cui H, Fan D, Joseph JD, McDonnell DR The homeodomain protein HOXB13 regulates the cellular response to androgens. Molec Cell. 2009;36(3):405-16. https://doi.org/10.1016/j.molcel.2009.10.020Norris JD, Chang C-Y, Wittmann BM, Stein R, Cui H, Fan D, Joseph JD, McDonnell DR The homeodomain protein HOXB13 regulates the cellular response to androgens. Molec Cell. 2009;36(3):405-16. https://doi.org/10.1016/j.molcel.2009.10.020Ewing CM, Ray Am, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin Aw, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WD, Cooney KA. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl J Med. 2012;366(2):141-9. https://doi.org/10.1056/NEJMoa1110000Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, partin AW, Shanmugam V, Izatt T, Sinari S, craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WD, Cooney KA. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl J Med. 2012;366(2):141-9. https://doi.org/10.1056/NEJMoa1110000Zabalza С.V., Meike A.M., Burdelski С., Wilczak W., Witt-Mer С., Kraft S., Krech T., Steurer S., Koop С., Hube-Magg С., Graefen M., Heinzer H., Minner S., Simon R., Sauter G., Schlomm T., Tsourlakis M.С. HOXB13 overexpression is an independent predictor of early pSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget. 2015;6(14):12822-34. https://doi.org/10.18632/oncotar-get.3431Zabalza c.V., Meike A.M., Burdelski c., Wilczak W., Wittmer c., Kraft S., Krech T., Steurer S., Koop c., Hube-Magg c., Graefen M., Heinzer H., Minner S., Simon R., Sauter G., Schlomm T., Tsourlakis M.c. HOXB13 overexpression is an independent predictor of early pSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget. 2015;6(14):12822-34. https://doi.org/10.18632/oncotar-get.3431Park cK, Shin SJ, Cho YA, Joo JW, Cho NH. HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker. Sci Rep. 2019;9(1):20205. https://doi.org/10.1038/s41598-019-56657-8park cK, Shin SJ, cho YA, Joo JW, cho NH. HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopatho-logic characteristics and its utility as potential diagnostic marker. Sci Rep. 2019;9(1):20205. https://doi.org/10.1038/s41598-019-56657-8Иванцов А.О., Насыров Р.А., Имянитов Е.Н., соколенко А.П. Морфологические особенности BRCA1-ассоциированных опухолей. Злокачественные опухоли. 2018;8(3s1):90-95. https://doi.org/10.18027/2224-5057-2018-8-3s1-90-95Ivancov A.O., Nasyrov R.A., Imyanitov E.N., Sokolenko A.p. Morfologicheskie osobennosti BRcA1-associirovannyh opuholej. Zlokachestvennye opuholi. 2018;8(3s1):90-95. (In Russ.). https://doi.org/10.18027/2224-5057-2018-8-3s1-90-95Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-57. https://doi.org/10.1200/JCO.2012.43.1882Castro E, Goh c, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer c, Douglas F, porteous ME, Donaldson A, Dorkins H, Izatt L, cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-57. https://doi.org/10.1200/JCO.2012.43.1882Мустафин А.Т., Султанов И.М., Галимзянов В.З., Андреева Д.М., Хуснутдинова Э.К., Ногманова В.А. Анализ частоты встречаемости мутации 5382INSC в гене BRCA1 у пациентов с раком предстательной железы и здоровых мужчин, проживающих на территории республике Башкортостан. Медицинский вестник Башкортостана. 2013;8(2):183-185. eLIBRARY ID: 20170260Pavlov V.N., Gilyazova I.R., Safiullin R.I., Mustafin A.T., Sultanov I.M., Galimzyanov V.Z., Andreeva D.M., Khusnutdi-nova E.K., Nogmanova V.A. Analysis of 5382INSC mutation in brca1 gene incidence in patients with prostate cancer and in healthy men living in the Republic of Bashkortostan. Medicinskij vestnik Bashkortostana. 2013;8(2):183-185. (In Russ.). eLIBRARY ID: 20170260Оськина Н.А., Боярских У.А., Ганов Д.И., Петрова В.Д., Лазарев А.Ф., Филипенко М.Л. Генетические исследования у пациентов с раком простаты. Сибирский онкологический журнал. 2009;2:151. eLIBRARY ID: 12919057Os'kina N.A., Boyarskih U.A., Ganov D.I., Petrov VD, Lasarev AF, Filipenko ML. Geneticheskie issledovaniya u pa-cientov s rakom prostaty. Sibirskij onkologicheskij zhurnal. 2009;2:151. (In Russ.). eLIBRARY ID: 12919057Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115-21. https://doi.org/10.1158/1078-0432.CCR-09-2871Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115-21. https://doi.org/10.1158/1078-0432.CCR-09-2871Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Gold-gar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55-59. https://doi.org/10.1038/ng879Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Gold-gar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55-59. https://doi.org/10.1038/ng879Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72(2):270-280. https://doi.org/10.1086/346094Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72(2):270-280. https://doi.org/10.1086/346094Zhen JT, Syed J, Nguyen KA. Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer. 2018;124(15):3105-3117. https://doi.org/10.1002/cncr.31316Zhen JT, Syed J, Nguyen KA. Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer. 2018;124(15):3105-3117. https://doi.org/10.1002/cncr.31316Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27(2):172-80. https://doi.org/10.1038/84808Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Can-non-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27(2):172-80. https://doi.org/10.1038/84808Camp NJ, Tavtigian SV. Meta-Analysis of Associations of the Ser217Leu and Ala541Thr Variants in ELAC2 (HPC2) and Prostate Cancer. Am J Hum Genet. 2002;71(6):1475-1478. https://doi.org/10.1086/344516Camp NJ, Tavtigian SV. Meta-Analysis of Associations of the Ser217Leu and Ala541Thr Variants in ELAC2 (HPC2) and Prostate Cancer. Am J Hum Genet. 2002;71(6):1475-1478. https://doi.org/10.1086/344516Djomkam ALZ, Beyeme Sala T, Baari Memba C. Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon. Prostate Cancer. 2019 Jun 19;2019:5974928. https://doi.org/10.1155/2019/5974928Djomkam ALZ, Beyeme Sala T, Baari Memba C. Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon. Prostate Cancer. 2019 Jun 19;2019:5974928. https://doi.org/10.1155/2019/5974928Cattaneo F, Venesio T, Molatore S, Russo A, Fiocca R, Frattini M, Scovassi AI, Ottini L, Bertario L, Ranzani GN. Functional analysis and case-control study of-160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Research. 2006;26: 4627-32. PMID: 17201188Cattaneo F, Venesio T, Molatore S, Russo A, Fiocca R, Frattini M, Scovassi AI, Ottini L, Bertario L, Ranzani GN. Functional analysis and case-control study of-160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Research. 2006;26: 4627-32. PMID: 17201188Hasnain I, Sharmin A, Hossain MA, Bellah SF, Rahman MM, Kadir MS, Sultana S, Mazid Ma, Rahman MM. Genetic polymorphisms in cDH1 and Exo1 Genes Elevate the prostate cancer Risk in Bangladeshi population. Tumour Biol. 2019;41(3):1010428319830837. https://doi.org/10.1177/1010428319830837Hasnain I, Sharmin A, Hossain MA, Bellah SF, Rahman MM, Kadir MS, Sultana S, Mazid MA, Rahman MM. Genetic polymorphisms in cDH1 and Exo1 Genes Elevate the prostate cancer Risk in Bangladeshi population. Tumour Biol. 2019;41(3):1010428319830837. https://doi.org/10.1177/1010428319830837Qin Z, Li X, Han P, Zheng Y, LiuH, Tang J, Yang C, Zhang J, Wang K, Qi X, Tang M, Wang W, Zhang W. Association Between polymorphic cAG Repeat Lengths in the Androgen Receptor Gene and Susceptibility to prostate cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2017;96(25):e7258. https://doi.org/10.1097/MD.0000000000007258Qin Z, Li X, Han P, Zheng Y, LiuH, Tang J, Yang C, Zhang J, Wang K, Qi X, Tang M, Wang W, Zhang W. Association Between polymorphic cAG Repeat Lengths in the Androgen Receptor Gene and Susceptibility to prostate cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2017;96(25):e7258. https://doi.org/10.1097/MD.0000000000007258Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl cancer Inst. 1994 Jun 1;86(11):872-3. https://doi.org/10.1093/jnci/86.11.872Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl cancer Inst. 1994 Jun 1;86(11):872-3. https://doi.org/10.1093/jnci/86.11.872Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hed-lund TE, Upadhya p. The human prostatic carcinoma cell line LNcap expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1992;52(3):515-20. PMID: 1370648Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya p. The human prostatic carcinoma cell line LNcap expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1992;52(3):515-20. PMID: 1370648Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, platz EA, Stampfer MJ, Giovannucci E. Vitamin d-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104(9):690-9. https://doi.org/10.1093/jnci/djs189Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, platz EA, Stampfer MJ, Giovannucci E. Vitamin d-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104(9):690-9. https://doi.org/10.1093/jnci/djs189Daremipouran MR, Beyene D, Apprey V., Naab TJ, Kassim OO, copeland Jr RL, Kanaan YM. The Association of a Novel Identified VDR SNp With prostate cancer in African American Men. Cancer Genomics Proteomics. 2019;16(4):245-255. https://doi.org/10.21873/cgp.20129Daremipouran MR, Beyene D, Apprey V., Naab TJ, Kassim OO, copeland Jr RL, Kanaan YM. The Association of a Novel Identified VDR SNp With prostate cancer in African American Men. Cancer Genomics Proteomics. 2019;16(4):245-255. https://doi.org/10.21873/cgp.20129Liu S, Cai H, cheng W, Zhang H, Pan Z, Wang D. Association of VDR polymorphisms ( Taq I and Bsm I) With prostate cancer: A New Meta-Analysis. J Int Med Res. 2017;45(1):3-10. https://doi.org/10.1177/0300060516668939Liu S, cai H, cheng W, Zhang H, pan Z, Wang D. Association of VDR polymorphisms ( Taq I and Bsm I) With prostate cancer: A New Meta-Analysis. J Int Med Res. 2017;45(1):3-10. https://doi.org/10.1177/0300060516668939Оськина Н.А., Боярских У.А., Лазарев А.Ф., петрова В.Д., Ганов Д.И., Тоначева О.Г., Лифшиц Г.И., Филипенко М.Л. Исследование влияния полиморфных замен в гене рецептора витамина D на риск развития рака предстательной железы в Западно-сибирском регионе РФ. Российский биотерапевтический журнал. 2012;10(3):67-70. eLIBRARY ID: 18884831Oskina N.A., Boyarskikh U.A., Lazarev A.F., Petrova V.D., Ganov D.I., Tonacheva O.G., Lifshits G.I., Filipenko M.L. Vitamin D receptor polymorphisms and risk of prostate cancer in the West Siberia. Russian Biotherapeutic journal. 2012;10(3):67-70. (In Russ.). eLIBRARY ID: 18884831Liu D, Liu Y, Ran L, Shang H, Li D. GSTT1 and GSTM1 polymorphisms and prostate cancer Risk in Asians: A Systematic Review and Meta-Analysis. Tumour Biol. 2013;34(5):2539-44. https://doi.org/10.1007/s13277-013-0778-zLiu D, Liu Y, Ran L, Shang H, Li D. GSTT1 and GSTM1 polymorphisms and prostate cancer Risk in Asians: A Systematic Review and Meta-Analysis. Tumour Biol. 2013;34(5):2539-44. https://doi.org/10.1007/s13277-013-0778-zBenabdelkrim M, Djeffal O, Berredjem H. GSTM1 and GSTT1 polymorphisms and Susceptibility to prostate cancer: A case-control Study of the Algerian population. Asian Pac J Cancer Prev. 2018;19(10):2853-2858. https://doi.org/10.22034/ApJcp.2018.19.10.2853Benabdelkrim M, Djeffal O, Berredjem H. GSTM1 and GSTT1 polymorphisms and Susceptibility to prostate cancer: A case-control Study of the Algerian population. Asian Pac J Cancer Prev. 2018;19(10):2853-2858. https://doi.org/10.22034/ARJcp.2018.19.10.2853Gong M, Dong W, Shi Z, Xu Y, Ni W, An R. Genetic polymorphisms of GSTM1, GSTT1, and GSTp1 with prostate cancer risk: a metaanalysis of 57 studies. PLoS One. 2012;7(11):e50587. https://doi.org/10.1371/journal.pone.0050587Gong M, Dong W, Shi Z, Xu Y, Ni W, An R. Genetic polymorphisms of GSTM1, GSTT1, and GSTp1 with prostate cancer risk: a metaanalysis of 57 studies. PLoS One. 2012;7(11):e50587. https://doi.org/10.1371/journal.pone.0050587Huang S, Wu F, Luo M, Ma L, Gao K, Li J, Wu W, Huang S, Yang Q, Liu K, Zhao Y, Li L. The glutathione S-transferase p1 341c>T polymorphism and cancer risk: a meta-analysis of 28 case-control studies. PLoS One. 2013;8(2):e56722. https://doi.org/10.1371/journal.pone.0056722Huang S, Wu F, Luo M, Ma L, Gao K, Li J, Wu W, Huang S, Yang Q, Liu K, Zhao Y, Li L. The glutathione S-transferase p1 341c>T polymorphism and cancer risk: a meta-analysis of 28 case-control studies. PLoS One. 2013;8(2):e56722. https://doi.org/10.1371/journal.pone.0056722Yu Z, Li Z, cai B, Wang Z, Gan W, chen H, Li H, Zhang P, Li H. Association Between the GSTp1 Ile105Val polymorphism and prostate cancer Risk: A Systematic Review and Meta-Analysis. Tumour Biol. 2013;34(3):1855-63. https://doi.org/10.1007/s13277-013-0727-xYu Z, Li Z, cai B, Wang Z, Gan W, chen H, Li H, Zhang P, Li H. Association Between the GSTp1 Ile105Val polymorphism and prostate cancer Risk: A Systematic Review and MetaAnalysis. Tumour Biol. 2013;34(3):1855-63. https://doi.org/10.1007/s13277-013-0727-xКунсбаева Г.Б., Гилязова И.Р., Янкина М.А., Климентова Е.А., Павлов В.Н., Хуснутдинова Э.К. Поиск мутаций в гене синдрома Блума (BLM) у пациентов с раком предстательной железы. Медицинская генетика. 2016;15(5):7-9. https://doi.org/10.1234/XXXX-XXXX-2016-5-7-9Kunsbaeva G.B., Gilyazova I.R., Yankina M.A., Klimentova E.A., Pavlov V.N., Khusnutdinova E.K. Search for Bloom syndrome gene (BLM) mutations in prostate cancer patients. Medical Genetics. 2016;15(5):7-9. (In Russ.) https://doi.org/10.1234/XXXX-XXXX-2016-5-7-9Davenport L. Men With BRcA2 Should Be Screened for prostate cancer. National Cancer Research Institute (NCRI) 2019 Cancer Conference; 2019.Davenport L. Men With BRCA2 Should Be Screened for Prostate Cancer. National Cancer Research Institute (NCRI) 2019 Cancer Conference; 2019.

The authors declare that there are no conflicts of interest present.